Literature DB >> 1574920

Molecular epidemiology of tick-borne encephalitis virus: cross-protection between European and Far Eastern subtypes.

H Holzmann1, M S Vorobyova, I P Ladyzhenskaya, E Ferenczi, M Kundi, C Kunz, F X Heinz.   

Abstract

Tick-borne encephalitis virus isolates from widely separated geographic regions of the USSR, six isolates from Hungary and one from France were compared with the European and Far Eastern prototype viruses. Peptide mapping by limited proteolysis yielded similar patterns for five selected isolates from the USSR. All isolates from Hungary and France exhibited the same reactivity pattern with a panel of 16 protein E-specific monoclonal antibodies, whereas 10 out of 12 isolates from the Soviet Union showed minor differences at certain epitopes. However, no correlation between geographic origin of the isolates and their antigenic structure was observed. No statistically significant difference in the degree of protection was detected when mice were immunized with the European prototype vaccine and challenged with three selected Asian isolates and one from the European part of the USSR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1574920     DOI: 10.1016/0264-410x(92)90376-u

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Tick-borne Encephalitis Vaccines.

Authors:  Axel T Lehrer; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011

2.  Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.

Authors:  Philip O Rabel; Christina B Planitzer; Maria R Farcet; Thomas R Kreil
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

3.  Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.

Authors:  C Schmaljohn; L Vanderzanden; M Bray; D Custer; B Meyer; D Li; C Rossi; D Fuller; J Fuller; J Haynes; J Huggins
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  A case of tick-borne encephalitis in Japan and isolation of the the virus.

Authors:  I Takashima; K Morita; M Chiba; D Hayasaka; T Sato; C Takezawa; A Igarashi; H Kariwa; K Yoshimatsu; J Arikawa; N Hashimoto
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

Review 5.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Single-dose vaccine against tick-borne encephalitis.

Authors:  Alexander A Rumyantsev; Ana P Goncalvez; Maryann Giel-Moloney; John Catalan; Yuxi Liu; Qing-sheng Gao; Jeff Almond; Harry Kleanthous; Konstantin V Pugachev
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

Review 7.  Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management.

Authors:  Marie Studahl; Lars Lindquist; Britt-Marie Eriksson; Göran Günther; Malin Bengner; Elisabeth Franzen-Röhl; Jan Fohlman; Tomas Bergström; Elisabeth Aurelius
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

8.  Diagnosis of tick-borne encephalitis by a mu-capture immunoglobulin M-enzyme immunoassay based on secreted recombinant antigen produced in insect cells.

Authors:  Anu Jääskeläinen; Xiuqi Han; Matthias Niedrig; Antti Vaheri; Olli Vapalahti
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

9.  Diagnostic potential and antigenic properties of recombinant tick-borne encephalitis virus subviral particles expressed in mammalian cells from Semliki Forest virus replicons.

Authors:  Lev Levanov; Suvi Kuivanen; Andrey Matveev; Sathyamangalam Swaminathan; Anu Jääskeläinen-Hakala; Olli Vapalahti
Journal:  J Clin Microbiol       Date:  2013-12-26       Impact factor: 5.948

Review 10.  Tick-borne viruses in Europe.

Authors:  Zdenek Hubálek; Ivo Rudolf
Journal:  Parasitol Res       Date:  2012-04-18       Impact factor: 2.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.